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DOI 10.1016/j.chembiol.2007.02.002Autism has received considerable at-
tention in the past few years; some say
its incidence is increasing. Upon closer
examination, however, the picture
blurs. A nascent initiative in Boston,
the Boston Autism Consortium, may
represent a pragmatic model for dealing
with complex diseases, one that in-
volves different institutions collaborat-
ing rather than competing and applying
research directly to patient care.
Autism is a heterogeneous neurode-
velopmental disorder. The canopy of
autism actually covers a number of
pervasive development disorders (re-
ferred to as ‘‘autism spectrum disor-
ders’’) that vary in severity. Popular
media accounts have asserted that
autism is rising due to environmental
triggers, but it may be a matter of shift-
ing diagnosis criteria. For example, the
CDC (www.cdc.gov) currently esti-
mates that from 1 in 500 to 1 in 150 chil-
dren is in some way autistic, depending
on the definition and method of screen-
ing. Autism appears to affect the brain
systemically and, in some cases, af-
fects the body as well. The disorder
strikes children across racial and eth-
nic lines, but affects boys four times
as often as girls. In the absence of an
organic biomarker, autism is diag-
nosed purely by impairment in commu-
nication and language development,
as well as certain rigid and repetitive
behaviors and preoccupations.
Many scientists are now focusing on
genetic causes, perhaps involving
combinations of dozens of genes.
There are only 2–3 statistically signifi-
cant findings linking autism to specific
chromosomal loci. And it is thought by
many researchers that patterns of
gene expression, in response to as
yet unknown environmental triggers,
make certain individuals more likely
to develop autism.
Some conceptualize autism not as
a black and white condition, but rather
in shades of grey; meaning that in an
affected family, one should find differ-
ent levels of autism ranging from be-
nign to severe. Notably, a sibling of
an autistic individual is more likely to
have an autism-spectrum disorder
compared to an unrelated person, al-
though estimates for the likelihood
vary. In the case of identical twins, dif-
ferent studies report anything from
a 36 to 91 percent chance, depending
on the screening method, that if one
twin is autistic, the other will be as
well. Essentially, nobody knows what
the important genes are or how they
code for the condition and interact
with each other or with environmental
triggers to translate into the disorder.
The Spirit of Collaboration Means
Actually Working Together in
Practice
This paucity of concrete information
provided the impetus for the launch of
the Autism Consortium in Boston last
year. Over 50 researchers drawn from
various disciplines at 11 of Boston’s
powerhouse institutions, including
Harvard, MIT, Tufts, the Broad Institute
for Genetic Research, Massachusetts
General Hospital, Boston University,
Boston Children’s Hospital, Beth Israel
Deaconess Medical Center, as well as
the Cambridge Healthcare Alliance,
are collaborating to improve screen-
ing, standardize diagnostic protocols,
efficiently translate laboratory results
back to the clinic, and ultimately iden-
tify potential targets for therapies.
The consortium is primarily funded
by private philanthropists, led by Paul
Marcus, a MIT alumnus with an interest
in developmental disabilities. Since the
project’s inception in 2006, Marcus
and his foundation have recruited other
donors and amassed between $10 and
$15 million for research. With fewer
federal funds available, the money
provides an attractive inducement for
competing institutions to collaborate.
The consortium hopes to eventually
apply for NIH funding as an entity,
although currently researchers work-
ing within its framework continue to
apply for individual and collaborative
grants.
This pan-institutional endeavor is
a pioneering one for the Boston bio-
medical community. The consortium
is directed by an executive committee
including Professor Mriganka Sur,
head of the Department of Brain and
Cognitive Science at MIT; Dr. Christo-
pher Walsh, chief of the Division of
Genetics at Childrens’ Hospital Bos-
ton; and Dr. James Gusella, professor
of neurogenetics at the Massachusetts
General Center for Human Genetic
Research. ‘‘This model is based on
the concept that the study of human
disease should be viewed as a cycle
that begins and ends with patients
and their families.’’ said Gusella.
‘‘Ultimately autism is a really hard prob-
lem. No one scientist can do it alone.’’
The executive committee coordi-
nates cross-institutional working
groups in areas including cognitive
neuroscience, clinical medicine, and
bioinformatics. At the core of the pro-
ject is the assembly of a large data
set of phenotypes of measured behav-
iors and biological samples from pa-
tients and their families. The hope is
that rigorous data analysis will reveal
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mechanisms and provide clues to po-
tential interventions. The next phase
is to obtain as many DNA samples
as possible from autistic individuals
and their family members, as certain
working groups are focusing on dis-
covering and characterizing autism-
related genes.
Parsing Out the Nitty-Gritty Details
The Autism Consortium has launched
the Autism Gene Discovery Project,
which is combing the entire human ge-
nome for clues to the causes of autism.
The Consortium is working with the
Broad Institute on completing a whole
genome association scan using data
from close to 800 families from the
Autism Genetic Research Exchange
(AGRE) database.
Researchers are using the Affyme-
trix GeneChip Human Mapping 500K
Array to screen more than 3,000
biological samples from the AGRE
repository. According to Dr. Susan
Santangelo, associate professor of
psychiatry, Harvard Medical School,
who is conducting gene mapping stud-
ies of autism, until fairly recently, genes
were implicated by linkage analysis,
which identifies regions of the genome
that are shared more frequently than by
chance among affected individuals.
These techniques work best when the
genetic contribution from any single
gene is large. Now gene mapping stud-
ies rely much more heavily on associa-
tion analyses, which are more powerful
when the contribution of any given
gene is small to moderate. These anal-
yses also can better pinpoint the chro-
mosomal locations of the genes in-
volved. This technique has become
more widely used as more appropriate
genetic markers such as single nucleo-
tide polymorphisms (SNPs) have be-
come available thanks to the Human
Genome Project. However, ‘‘the entire
AGRE collection does not yet have
a large amount of phenotypic data on
all the families,’’ said Santangelo, ‘‘Be-
cause this was begun several years
ago, they mainly focused on the collec-
tion of diagnostic information. Most in
the field now agree that diagnostic
data alone are not going to get us there
because we’re dealing with very het-
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The AGRE database was cofounded in
1997 under the auspices of the Cure
Autism Now Foundation and a scientific
steering committee chaired by Dr.
Daniel Geschwind, who directs the
Center for Autism Research and Treat-
ment (CART) at UCLA. CART is collect-
ing longitudinal information on sibling
pairs, in which one sibling of an autistic
patient is followed from infancy into
early childhood. The AGRE database
is now cofunded by NIMH and contains
biomaterials from thousands ofpatients
as well as clinical and psychological
phenotype data such as language
skills, IQ measurements, and medical
information concerning patients and
relatives. AGRE is used by 140 re-
searchers around the world. ‘‘It is
not just about finding genes,’’ said
Geschwind. ‘‘It is about finding genes,
understanding how they cause autism
or might contribute to autism suscep-
tibility’’ as well as ‘‘how they relate to
different subsets of autism, because
we have really begun to think about
autism as ‘the autisms.’ That is, autism
is a syndrome with likely hundreds of
distinct causes.’’
Another data collection effort is un-
derway at the MIND Institute at the
University of California, Davis, headed
by David Amaral, professor of medical
psychiatry. Data is being collected on
1,500 patients over five years. MIND
is also combining phenotype informa-
tion with data on environmental toxins
as well as looking for biomarkers.
In addition to drawing on the AGRE
resources, the Autism Consortium is
also collaborating with scientists at
Johns Hopkins University, who are in
the third year of an autism study using
the 500K array to scan 600 families.
The study is led by Professor Aravinda
Chakravarti, director of the McKusick-
Nathans Institute of Genetic Medicine,
and is funded through the NIH.
Looking for the Larger Picture
The Learning and Developmental Dis-
abilities Evaluation and Rehabilitation
Services (LADDERS) program at Mass
General Hospital is submitting data on
80 patients to the Autism Consortium
in the first year of a two year collabora-
tion. According to LADDERS director7 ª2007 Elsevier Ltd All rights reservedDr. Margaret Bauman, the earlier
children are diagnosed and put in
treatment, the better they respond.
Treatment can comprise intensive edu-
cation, physical, speech, and language
therapy and drugs. LADDERS also
deals with the medical problems cor-
related to autism. Interestingly, Bau-
man’s program looks for metabolic
clues to serve as more precise ‘‘finger-
prints’’ for the condition over behavioral
observations. She emphasizes the im-
portance of making families partners,
rather than subjects, in ongoing re-
search. ‘‘You would want to hang on
to your subjects once you have them.’’
Bauman said. ‘‘You don’t want to
make them feel like, pardon the expres-
sion, guinea pigs. You want them to feel
like they are part of a larger picture.’’
Getting Your Shirt on Straight
Researchers are in it for the long haul,
but autism patients and their families
have more immediate concerns. Mary
Kae Marinac, a consultant north of
Boston, has 12 year old, identical twin
sons, ‘‘happy, wonderful kids, both
with autism.’’ ‘‘They tend to be what is
considered on [the] lower end of the
spectrum, in terms of communications
and activities of daily living,’’ said Mari-
nac. ‘‘They cannot read or write, they
still struggle [with] whether a shirt is
oriented frontwards or backwards,
and only one is newly capable of wip-
ing [after] bowel movements. They re-
quire extensive support.’’ The twins
attend a special school with a ratio
of one staff member to every two stu-
dents. ‘‘Without extreme structure and
rigidity in their day, they fall apart.’’
said Marinac. For families like this, re-
sults from the Autism Consortium and
other research efforts cannot come
soon enough.
Ultimately, the Autism Consortium
wants to find ways to improve the
quality of life for people with autism.
In the meantime, this collaborative
effort may lead to prenatal diagnostics
and to improved standards of care and
support for patients and their families.
But to decipher this puzzle, the first
challenge is to find and then fit the
scattered pieces together.
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